Gene · 11255
Papers1,482
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 1,482
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Histamine H3 receptor antagonists/inverse agonists: a patent review (October 2017 - December 2023) documenting progress. | Expert Opin Ther Pat | 2025 | 39757430 | PubTator, text mining | PubMed |
| Working memory processes and the histamine-3 receptor in schizophrenia: a [11C]MK-8278 PET-fMRI study. | Psychopharmacology (Berl) | 2025 | 39710764 | PubTator, text mining | PubMed |
| Histamine receptor agonism differentially induces immune and reparative healing responses in biomaterial-facilitated tissue repair. | Biomaterials | 2025 | 39586217 | PubTator, text mining | PubMed |
| Data-driven score tuning for ChooseLD: A structure-based drug design algorithm with empirical scoring and evaluation of ligand-protein docking predictability. | Biophys Physicobiol | 2024 | 39802744 | PubTator, text mining | PubMed |
| Guanidine Derivative ADS1017, a Potent Histamine H3 Receptor Antagonist with Promising Analgesic Activity and Satisfactory Safety Profile. | ACS Chem Neurosci | 2024 | 39652796 | PubTator, text mining | PubMed |
| Histamine H3 receptor inverse agonists/antagonists influence intra-regional cortical activity and inter-regional synchronization during resting state: an exploratory cortex-wide imaging study in mice. | Mol Brain | 2024 | 39605021 | PubTator, text mining | PubMed |
| Virtual Screening Approaches to Identify Promising Multitarget-Directed Ligands for the Treatment of Autism Spectrum Disorder. | Molecules | 2024 | 39598660 | PubTator, text mining | PubMed |
| First Report on Cationic Triphenylphosphonium Compounds as Mitochondriotropic H3R Ligands with Antioxidant Properties. | Antioxidants (Basel) | 2024 | 39594487 | PubTator, text mining | PubMed |
| Regulatory roles of histamine receptor in astrocytic glutamate clearance under conditions of increased glucose variability. | Biochem Pharmacol | 2024 | 39510195 | PubTator, text mining | PubMed |
| Anxiolytic- and antidepressive-like effects of harmaline in mice are mediated via histamine H3 receptor blockade. | Biochem Biophys Res Commun | 2024 | 39467356 | PubTator, text mining | PubMed |
| Recent progress in therapeutic applications of fluorinated five-membered heterocycles and their benzo-fused systems. | RSC Adv | 2024 | 39463482 | PubTator, text mining | PubMed |
| Histamine stimulates human microglia to alter cellular prion protein expression via the HRH2 histamine receptor. | Sci Rep | 2024 | 39462031 | PubTator, text mining | PubMed |
| Alleviation of Autophagic Deficits and Neuroinflammation by Histamine H3 Receptor Antagonist E159 Ameliorates Autism-Related Behaviors in BTBR Mice. | Pharmaceuticals (Basel) | 2024 | 39458934 | PubTator, text mining | PubMed |
| Potential differences in receptor-mediated G-protein activation in postmortem human hippocampal membranes prepared from healthy controls and suicide victims. | Neuropsychopharmacol Rep | 2024 | 39352115 | PubTator, text mining | PubMed |
| Betahistine's Neuroprotective Actions against Lipopolysaccharide-Induced Neurotoxicity: Insights from Experimental and Computational Studies. | Brain Sci | 2024 | 39335372 | PubTator, text mining | PubMed |
| Opportunities and challenges in the therapeutic exploitation of histamine and histamine receptor pharmacology in inflammation-driven disorders. | Pharmacol Ther | 2024 | 39306197 | PubTator, text mining | PubMed |
| Discovery of New Highly Potent Histamine H3 Receptor Antagonists, Calcium Channel Blockers, and Acetylcholinesterase Inhibitors. | ACS Chem Neurosci | 2024 | 39208251 | PubTator, text mining | PubMed |
| Tackling Neuroinflammation in Cognitive Disorders with Single-targeted and Multi-targeted Histamine H3 Receptor Modulators. | Curr Top Med Chem | 2024 | 39185652 | PubTator, text mining | PubMed |
| Scutellarein derivatives with histamine H3 receptor antagonism and cholinesterase inhibitory potency as multi target-directed ligands for possible Alzheimer's disease therapy. | Bioorg Chem | 2024 | 39126870 | PubTator, text mining | PubMed |
| AR71, Histamine H3 Receptor Ligand-In Vitro and In Vivo Evaluation (Anti-Inflammatory Activity, Metabolic Stability, Toxicity, and Analgesic Action). | Int J Mol Sci | 2024 | 39125607 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/11255/papers?page=4